FDA Approves Bevacizumab-adcd for  Six Types of Cancer

On September 28, 2022, the U.S. Food and Drug Administration (FDA) approved Vegzelma® (bevacizumab-adcd), a biosimilar to Avastin® (bevacizumab), for the treatment of metastatic colorectal cancer; recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; persistent, recurrent, and metastatic cervical and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

For more information read the Business Wire press release.

Posted 9/28/2022